Israeli company Vaxil Biotherapeutics, which is developing vaccines for cancer and tuberculosis, has received a $3 million investment. The investment was made by Yorkville Advisors, which will transfer the funds over the next five years.
Vaxil was founded in late 2006 and is headquartered at the Weizmann Science Park.
Related posts
Israeli AI Safety Tool Among TIME’S Best Inventions For 2024
October 31, 2024
TAU Team Discovers Mechanism To Eliminate Cancerous Tumors
October 30, 2024
Ashdod Port Investing In Startups As Part Of Innovation Strategy
October 29, 2024
BGU Develops Fast Fact Checking Via News Sources Not People
October 28, 2024
Facebook comments